Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071)

2018 ◽  
Vol 82 (4) ◽  
pp. 733-739 ◽  
Author(s):  
Markus Moehler ◽  
◽  
Arno Schad ◽  
Annett Maderer ◽  
Ajlan Atasoy ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Gastric Cancer ◽  
Line Treatment ◽  
First Line ◽  
First Line Treatment

scholarly journals Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial

2019 ◽  
Vol 84 (6) ◽  
pp. 1365-1365
Author(s):  
Fernando Rivera ◽  
C. Romero ◽  
P. Jimenez-Fonseca ◽  
M. Izquierdo-Manuel ◽  
A. Salud ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Her2 Positive ◽  
First Line Treatment

Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine.

Pazopanib and 5-FU/oxaliplatin as first-line treatment in advanced gastric cancer: PaFLO, a randomized phase II study from the AIO (Arbeitsgemeinschaft Internistische Onkologie).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 4033-4033 ◽  
Author(s):  
Peter C. Thuss-Patience ◽  
Salah-Eddin Al-Batran ◽  
Jens T Siveke ◽  
Nils Homann ◽  
Peter Malfertheiner ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Advanced Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Line Treatment ◽  
First Line ◽  
Randomized Phase Ii ◽  
First Line Treatment
Sign in / Sign up

Export Citation Format

Share Document